PMC:7321036 / 129474-130050
Annnotations
LitCovid-PMC-OGER-BB
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1775 | 139-141 | SO:0001811 | denotes | he |
T1776 | 173-174 | SP_6;NCBITaxon:9606 | denotes | a |
T1785 | 207-208 | NCBITaxon:6239 | denotes | c |
T1788 | 211-212 | NCBITaxon:9606 | denotes | i |
T1793 | 241-242 | NCBITaxon:9606 | denotes | B |
T1802 | 336-339 | SO:0001811 | denotes | rti |
T1804 | 453-455 | CHEBI:32958;CHEBI:32958 | denotes | Ph |
T1811 | 540-541 | GO:0006468 | denotes | l |
T1812 | 541-542 | GO:0043234 | denotes | s |
T1813 | 542-548 | GO:0043234 | denotes | pring |
T1814 | 555-558 | GO:0043234 | denotes | nce |
T1816 | 564-567 | GO:0032991 | denotes | xes |
T1817 | 568-569 | GO:0032991 | denotes | P |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T212 | 22-25 | http://purl.obolibrary.org/obo/CLO_0051582 | denotes | has |
T213 | 108-111 | http://purl.obolibrary.org/obo/CLO_0051582 | denotes | has |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T53882 | 91-93 | Chemical | denotes | La | http://purl.obolibrary.org/obo/CHEBI_33336 |
LitCovid-PD-HP
Id | Subject | Object | Predicate | Lexical cue | hp_id |
---|---|---|---|---|---|
T17 | 419-427 | Phenotype | denotes | Oncology | http://purl.obolibrary.org/obo/HP_0002664 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1025 | 0-81 | Sentence | denotes | The Krogan laboratory has received research support from Vir Biotechnology and F. |
T1026 | 82-100 | Sentence | denotes | Hoffmann-La Roche. |
T1027 | 101-203 | Sentence | denotes | K.M.S. has consulting agreements for the following companies involving cash and/or stock compensation: |
T1028 | 204-471 | Sentence | denotes | Black Diamond Therapeutics, BridGene Biosciences, Denali Therapeutics, Dice Molecules, eFFECTOR Therapeutics (zotatifin and tomivosertib), Erasca, Genentech/Roche, Janssen Pharmaceuticals, Kumquat Biosciences, Kura Oncology, Merck, Mitokinin, Petra Pharma, Qulab Inc. |
T1029 | 472-576 | Sentence | denotes | Revolution Medicines (WDB002), Type6 Therapeutics, Venthera, and Wellspring Biosciences (Araxes Pharma). |